top of page

Clog-free Filters.            For Bioreactors.

Screenshot 2025-06-04 at 1.07_edited.jpg
We’re building the world’s first inertial microfluidic perfusion filter for bioreactors that removes dead cells, reduces impurities, and keeps yield steady for weeks.

“We lose yield in membrane filters — this could be huge.” – MNC R&D Lead. “Dead cell removal during perfusion? Game-changing.” – Biotech Stakeholder. “We’re always looking for clean, scalable alternatives.” – CDMO Director

Clogging Kills Continuity

Membrane filters foul during runs, causing interruptions, yield loss, and emergency cleanups.

 What’s Going Wrong with Traditional Filtration?

Impurities Compromise Safety

Residual Host Cell Proteins (HCPs) can escape membranes, reducing product purity and risking downstream compliance.

Downtime Costs Millions

Every cleaning cycle, membrane replacement, or run stoppage bleeds revenue — especially in high-throughput lines.

Picture 1.png

What Makes CelltoMix a Breakthrough in Cell Filtration

1

Clog-Free Operation

Run for weeks without a single stoppage.

Engineered with advanced microfluidics, CelltoMix eliminates the risk of clogging — even during prolonged use. This ensures consistent performance and a stable yield over time, reducing downtime and maintenance compared to traditional filters.

optimized_A_high-resolution_digital_photograph_showcases_a_c_edited.jpg

2

Removes Dead Cells in Real Time

Cleaner product. Simpler downstream.

Removes 25–50% of dead cells during perfusion, cutting HCPs before they reach purification.

optimized_A_digital_illustration_with_text_overlay_displays_.png

3

Boosts Viability by 2–4%

Stronger culture. Higher return.

Higher live cell density = higher product yield.
Proven +14% titer vs membrane ATF systems.

optimized_A_2D_digital_graphic_features_a_chart_against_a_bl_edited.jpg

4

Plug-and-Play + GMP-Ready

Bioreactor ready from Day 1.

Works from 2L to 2000L. No installation. Fully disposable.
OPC-compatible. Integrates with Segflow & ProSIA.

optimized_A_high-resolution_digital_photograph_showcases_a_G.png

How It Works

What We Stand For

Innovation. Precision. Performance.

At CelltoMix, we are redefining bioprocessing through next-generation microfluidic technology. Founded by leading scientists and engineers, our mission is to solve the industry’s toughest filtration challenges — starting with clog-free, high-yield microfilters.

With a science-first approach and over two decades of international research experience behind our core team, we’re building tools that increase cell culture productivity, reduce operational downtime, and optimize bioreactor performance.

We believe innovation in life sciences begins at the microscopic level — and that’s exactly where we thrive.

Our Team

Precision. Expertise. Global excellence.

2025-04-26 02.37.20.jpg
Dr. Shireen Goh

Co-Founder

Dr. Shireen Goh is scientific co-founder of Celltomix and Associate Professor at SUTD, specializing in microfluidics and biomanufacturing with technologies licensed to industry, including Erbi Biosystems (acquired by Merck in 2022).

  • Linkedin
danny_pass.jpg
Dr. Danny van Noort

Co-Founder

Dr. Danny van Noort is an internationally recognized researcher with 25+ years of experience in physics, microtechnology, and biomedical engineering. He specializes in biosensors, DNA computers, organ-on-chips, and 3D cell models, with numerous publications and global lectures.

  • Linkedin
WhatsApp Image 2025-04-26 at 16.44.37.jpeg
Leo Siang Kwong

Co-Founder

Leo Siang Kwong is an expert in digital transformation and automation, with 25+ years of experience in technology and engineering. A certified PMP and ScrumMaster, he specializes in leading large-scale digital initiatives, smart manufacturing, and ERP solutions, translating business vision into scalable innovation.

  • Linkedin
pranav.jpeg
Pranav Garg

Co-Founder

Pranav Garg is a young co-founder with a strong foundation in marketing and entrepreneurship. As the founder of a successful marketing firm in India, he specializes in strategic marketing and business development, driving growth and innovation in his ventures.

  • Linkedin

CelltoMix in Numbers

4

Employees

S$ 1.5M

In Investment discussions

Proof of Concept

BGS appoints Andrew Kim as Board Director

AGIAI Science Journal
November 2035

Therapeutics Giant Announces Collaboration With San Francisco’s BGS

Biotech Frontier Review
May 2035

There’s a New Kid in Town, Changing the Face of Genetic Engineering.

IBRM Magazine
March 2035

Join The CelltoMix Newsletter

Be the first to receive the latest news and updates.

bottom of page